Scientists Discover How C. difficile Toxin Hijacks Macrophages to Fuel Gut Inflammation
Researchers identify CD44 as the macrophage receptor for TcdB toxin, revealing a succinylation-driven inflammatory pathway with new therapeutic implications.
Summary
A 2025 study in Gut Microbes reveals that CD44, a surface protein on macrophages, acts as a receptor for TcdB — the primary virulence toxin of Clostridioides difficile. When TcdB or its frizzled-binding domain (FBD) binds CD44, it suppresses the enzyme SUCLG2, triggering succinylation of lysine-158 on CD44. This post-translational modification amplifies NF-κB signaling, driving pro-inflammatory cytokine production that damages the gut epithelial barrier. CRISPR knockout experiments in cells and mice confirmed CD44's essential role. Blocking the TcdB–CD44 interaction successfully reduced inflammation, pointing toward a novel therapeutic strategy for C. difficile-associated disease.
Detailed Summary
Clostridioides difficile infection is a leading cause of antibiotic-associated colitis and can progress to life-threatening complications. Its primary toxin, TcdB (~270 kDa), is considered the main driver of disease, partly by activating macrophages to release inflammatory cytokines that worsen intestinal barrier damage. Despite this, the specific macrophage surface receptor mediating TcdB's inflammatory effects — and the downstream molecular mechanism — remained unknown.
This study focused on the frizzled-binding domain (FBD) of TcdB, a subdomain within the delivery and receptor-binding region. Researchers showed that FBD alone triggered macrophage inflammation (IL-1β, IL-6 secretion) at levels comparable to full-length TcdB, but crucially, FBD lacked cytotoxicity even at high concentrations (1000 pM), making it an ideal tool to study inflammatory receptor binding without confounding cell death effects.
Using FBD as a bait protein in pull-down/mass spectrometry assays on PMA-differentiated THP-1 macrophages, CD44 was identified as the primary macrophage-surface binding partner for TcdB/FBD. This finding was validated through CRISPR/Cas9-mediated CD44 knockout in macrophages and in CD44 knockout mice, both of which showed markedly reduced inflammatory responses to TcdB/FBD. Co-immunoprecipitation and surface plasmon resonance confirmed direct physical interaction between FBD and CD44.
To uncover the downstream molecular mechanism, the team employed 4-D label-free succinylation quantitative modification proteomics — a cutting-edge approach to capture lysine succinylation changes across the proteome. TcdB/FBD binding to CD44 was found to suppress SUCLG2 (succinyl-CoA ligase subunit), elevating succinyl-CoA availability and driving succinylation of CD44 at lysine residue 158 (K158). This modification enhanced NF-κB nuclear translocation and transcriptional activity, amplifying inflammatory cytokine production. Mutating K158 to arginine (blocking succinylation) or to glutamate (mimicking constitutive succinylation) confirmed the functional importance of this specific site.
Finally, the researchers demonstrated that competitive blockade of the TcdB–CD44 interaction — using CD44-neutralizing antibodies or recombinant CD44 extracellular domain as a decoy — significantly attenuated macrophage inflammation in vitro and reduced disease severity in a mouse model of C. difficile infection. These results establish the TcdB/FBD–CD44–K158 succinylation–NF-κB axis as a therapeutically actionable pathway for preventing and treating C. difficile-associated disease.
Key Findings
- CD44 on macrophages is a direct receptor for TcdB and its frizzled-binding domain (FBD), confirmed by CRISPR knockout.
- FBD triggers macrophage IL-1β and IL-6 secretion comparable to full TcdB but causes no cytotoxicity.
- TcdB/FBD binding suppresses SUCLG2, elevating succinyl-CoA and causing CD44 K158 succinylation.
- CD44 K158 succinylation drives NF-κB nuclear translocation and amplifies the inflammatory cytokine cascade.
- Blocking the TcdB–CD44 interaction reduced macrophage inflammation and C. difficile disease severity in mice.
Methodology
The study used PMA-differentiated THP-1 human macrophages and Caco-2 intestinal epithelial cells as in vitro models, with CRISPR/Cas9 CD44 knockout cells and knockout mice for in vivo validation. Receptor identification employed FBD pull-down with mass spectrometry; downstream signaling was mapped using 4-D label-free succinylation quantitative proteomics combined with site-directed mutagenesis.
Study Limitations
The study relies primarily on a THP-1 macrophage cell line model; primary human colonic macrophage data are limited. Mouse C. difficile infection models may not fully replicate human disease complexity, and the translational feasibility of CD44-blocking therapeutics requires further preclinical development.
Enjoyed this summary?
Get the latest longevity research delivered to your inbox every week.
Enter your email to subscribe: